Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer,  announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8M non-dilutive CLIN2 grant to support the clinical development of SRN-101, Siren's lead investigational AAV immuno-gene therapy for high-grade glioma brain cancers.

The award follows the U.S. Food and Drug Administration's (FDA) clearance of Siren's first Investigational New Drug (IND) application earlier this year, which advanced the Company to clinical stage and enabled a Phase 1/2 trial in adult patients with recurrent high-grade glioma. CIRM's transformative CLIN2 funding will support the conduct of that trial and the activities required to evaluate SRN-101 in patients.

SRN-101 is built on Siren's Universal AAV Immuno-Gene Therapy platform, designed to enable localized, durable delivery of immune-modulating payloads directly within tumors. The program has received Fast Track, Orphan Drug and Rare Pediatric Disease designations from the FDA. CIRM previously supported the program at the translational stage with a $4M non-dilutive TRAN1 grant, and today's award extends that support into the clinic.

We are profoundly grateful to CIRM, who backed this science at its earliest stage and is now standing with us as we enter the clinic," said Nicole K. Paulk, PhD, Founder, CEO, and President of Siren Biotechnology. "High-grade gliomas remain among the hardest cancers to treat, and the patients who live with them cannot wait. This funding propels SRN-101 toward the patients who need it, made possible by the vision of the people of California.”

This research is supported by the California Institute for Regenerative Medicine (CIRM), a State of California agency that funds regenerative medicine, stem cell, and gene therapy research (Grant numbers: CLIN2-19526 and TRAN1-15325).